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Objective: Thyroid autoimmunity (TA) is the most prevalent autoimmune disease in women of repro-
ductive age and is often accompanied by subclinical hypothyroidism (SCH). Both TA and SCH have been
associated with adverse pregnancy outcomes, but their relative inﬂuence is unclear. Therefore, we car-
ried out a meta-analysis to evaluate the sole effect of TA on pregnancy outcomes in euthyroid women
undergoing assisted reproductive technology.
Materials and Methods: Literature searches were conducted on Pubmed, EMBASE, and the Cochrane
Controlled Trials Register Database from inception to May 2014.
Results: In euthyroid women whose SCH status is unknown, those with positive antithyroid antibodies
(ATA) had a higher miscarriage rate [pooled relative risk (RR) ¼ 1.638; 95% conﬁdence interval (CI), 1.228
e2.185] and a lower delivery rate (pooled RR ¼ 0.856; 95% CI, 0.759e0.965) than those with negative
ATA. Clinical pregnancy rates were similar between groups. However, clinical pregnancy rate, miscarriage
rate, and delivery rate were all comparable between ATA-positive and ATA-negative euthyroid women
without SCH.
Conclusion: TA per se does not impair assisted reproductive treatment outcomes in women without SCH.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Thyroid autoimmunity (TA) is deﬁned as the presence of anti-
thyroid antibodies (ATA), speciﬁcally antithyroglobulin (anti-TG)
and antithyroid peroxidase (anti-TPO). It is the most prevalent
autoimmune disease in women of reproductive age, with a preva-
lence of 5e15% [1], and in women with infertility, the prevalence is
10e31% [2]. TA was shown to be associated with many kinds of
adverse obstetric outcomes, such as preterm delivery, placental
abruption, and low birth weight [3]. The association with miscar-
riage was ﬁrst reported in 1990 [1]. Subsequently, the number of
studies on the association between TA and miscarriage increased
substantially, however, the results were conﬂicting. Although
several meta-analyses showed that TAwas associated with a higherand Stem Cell Engineering,
a 410078, China.
bstetrics & Gynecology. Published brisk of miscarriage in women who had conceived spontaneously
[4,5], the association between TA and miscarriage was still unclear
in infertile women undergoing assisted reproductive technologies
(ART).
TA has been found to be related to subclinical hypothyroidism
(SCH) [6e8], which is characterized by increased serum thyroid
stimulating hormone (TSH) concentration but normal concentra-
tion of free thyroxine (FT4) [9]. A study investigated 6288 euthyroid
women with no history of thyroid disorder undergoing their ﬁrst
in vitro fertilization (IVF) cycle and found that 26% of ATA-positive
women also had SCH compared with 16.8% of ATA-negative
women, suggesting that women with positive ATA were more
likely to have SCH [8]. In another study [10], thyroid function values
and anti-TPO status were measured in 668 pregnant women
without known thyroid disease to determine the 1st-trimester
thyroid function values and associations with anti-TPO status. It
was found that TSH concentration in anti-TPO-positive womenwas
nearly double that of anti-TPO-negative women (1.1 mIU/L vs.y Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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to ART treatment, at 12 and 30 weeks after conception, were all
signiﬁcantly higher in anti-TPO positive women [11].
However, SCH has also been reported to be associated with a
higher risk of miscarriage [3]. It is therefore difﬁcult to determine if
miscarriage resulted from TA or underlying SCH, especially when
previous meta-analyses [4,12] only included euthyroid women
without overt thyroid disorder, and did not take SCH into consid-
eration. We undertook this meta-analysis again to observe the ef-
fect of TA per se on pregnancy outcomes in euthyroid women
undergoing ART, and also the effect of excluding patients with SCH.
Materials and methods
Search strategy and identiﬁcation of literature
Literature searches were conducted via Pubmed, EMBASE, and
the Cochrane Controlled Trials Register Database from inception to
May 2014. A combination of medical subject headings (MeSH) and
text words were used for search: “Fertilization in Vitro [MeSH],”
“Reproductive Techniques, Assisted [MeSH],” “Sperm Injections,
Intracytoplasmic [MeSH],” “IVF,” “ART,” “ICSI,” “Thyroid Gland
[MeSH],” “autoantibodies [MeSH],” “(Thyroid) AND antibody,”
“thyroglobulin [MeSH Terms],” “thyroid microsomal antibodies,”
[Supplementary Concept],” “thyroperoxidase,” “thyroid peroxi-
dase,” “Thyroid Autoimmunity,” “Pregnancy Outcome[MeSH
Terms],” “Pregnancy[MeSH Terms],” “Abortion, Spontaneous[MeSH
Terms],” “Delivery, Obstetric[MeSH Terms],” “abortion,” “miscar-
riage,” “labor,” “delivery,” “parturition.” The search items were set
by the authors and a professional information retrieval practitioner.
No language restrictions were placed on any search. A manual
search was also applied to identify as many relative articles as
possible.
Study selection and outcome measures
Studies were selected if the target population was euthyroid
women undergoing ART whose level of thyroid function and ATA
was measured. “Euthyroid” women were deﬁned as those with
normal concentrations of triiodothyronine (T3) and thyroxine (T4),
with no overt thyroid disorders, and with no history of thyroid
diseases. To eliminate the inﬂuence of failed IVF treatment on
thyroid function and pregnancy, studies involving multiple IVF
procedures were excluded. In addition, studies were excluded if
participants had SCH, or the data of SCH patients could not be
separated.
Studies were included if they were a cohort design, including
prospective and retrospective, comparing ATA-positive women
with ATA-negative controls. There were no limitations for language
or publications type, therefore, conference abstracts could be
included.
The outcome measures of interest were clinical pregnancy,
miscarriage, and delivery rates. For the purpose of this review,
clinical pregnancy was deﬁned as the observation of a pregnancy
sac on ultrasound at least 4 weeks after embryo transfer. Miscar-
riage was deﬁned as the loss of clinical pregnancy.
Data extraction
Two reviewers independently selected eligible studies and
extracted the relevant data as deﬁned below. Any disagreements
were resolved via discussion. A standardized data extraction form
was used for data extraction and included general characteristics of
the study (author, year of publication, country, study design, sam-
ple size, study period), characteristics of the study groups, theircomparability on baseline characteristics (age, body mass index,
etiology of infertility, number of oocytes retrieved and embryos
transferred, hormone concentrations, thyroid function tests),
methodology (ART types, protocol, deﬁnition of measure outcomes,
thyroid autoantibodies and hormone measurement method,
threshold and time of measurement, study quality), and outcomes
(clinical pregnancies, miscarriages, deliveries).
The NewcastleeOttawa Scale [13] was applied for quality as-
sessments, including selection of cases and controls, comparability
at baseline, and completeness of follow up. A quantitative appraisal
of overall quality of each observational study was obtained, and
scores ranged from 0 to 9.Statistical analysis
If the chi-square test showed there was no signiﬁcance of het-
erogeneity among the included studies (p > 0.05), the ﬁxed model
was applied to calculate the pooled relative risk (RR) and its 95%
conﬁdence interval (CI). When heterogeneity among the included
studies was signiﬁcant (p < 0.05), the randommodel was applied to
calculate the pooled RR and its 95% CI. Egger's test was applied to
assess the publication bias.
Statistical analyses were performed using Stata/SE 12.0 for
Windows (StataCorp. LP, College Station, TX, USA). The study was
completed in accordance with the standards of meta-analysis of
observational studies in epidemiology groups [14].Results
Search results
The search strategy identiﬁed 300 potentially relevant studies,
and a ﬂowchart summarizing the search results is provided
(Figure 1). Of these 300 publications, 280 were excluded on the
basis of title and abstract. The remaining 20 publications were read
independently by two reviewers in full. Among these, 10 articles
were excluded because the women were not undergoing their ﬁrst
ART procedure [15e24], one because no data were given [25], and
one because thyroid function was not tested [26]. Of the eight ar-
ticles remaining [8,11,27e32], four were used in the ﬁnal analysis
[8,27,28,32] once patients with SCH were excluded.
The eight studies included in the systematic review were pub-
lished between 2003 and 2014 and report data on 5286 infertile
women including 675 ATA-positive and 4611 ATA-negative women
(Table 1). In the ﬁnal analysis, four studies were included with data
on 1855 infertile women including 292 ATA-positive and 1563 ATA-
negative women. The quality assessments of all studies are pre-
sented in Table 2.Outcomes
Clinical pregnancy rate
In subfertile euthyroid women whose SCH status is unknown
undergoing ART, positive-ATA women showed a similar clinical
pregnancy rate compared with negative-ATA women (ﬁxed-effects
RR ¼ 0.967; 95% CI, 0.883e1.059; p ¼ 0.467; Figure S1). The het-
erogeneity test result was low (I2 ¼ 11.2%), and Egger's test result
was not signiﬁcant (p ¼ 0.960).
Similar results were shown in subfertile euthyroid women
without SCH undergoing ART (ﬁxed-effects RR ¼ 0.993; 95% CI,
0.853e1.155; p ¼ 0.923; Figure 2). Again, heterogeneity was low
(I2 ¼ 0%) and Egger's test result was nonsigniﬁcant (p ¼ 0.782).
Figure 1. Study selection process for meta-analysis of effect of thyroid autoimmunity on assisted reproduction treatment outcomes. SCH ¼ subclinical hypothyroidism.
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In subfertile euthyroid women whose SCH status is unknown
undergoing ART, women with positive ATA had a signiﬁcantly
higher miscarriage rate compared with those with negative ATA
(ﬁxed-effects RR¼ 1.580, 95% CI,1.297e1.925; p < 0.001; Figure S2).
No sign of heterogeneity was detected (I2 ¼ 0%), and Egger's test
showed no sign of publication bias (p ¼ 0.428).
However, in subfertile euthyroid women without SCH under-
going ART, the women with positive ATA showed a similar
miscarriage rate to those with negative ATA (ﬁxed-effects
RR ¼ 1.445; 95% CI, 0.970e2.154; p ¼ 0.070; Figure 3). No sign of
heterogeneity was detected (I2 ¼ 0%), and Egger's test showed no
sign of publication bias (p ¼ 0.158).
Delivery rate
In subfertile euthyroid women whose SCH status is unknown
undergoing ART, women with positive ATA had signiﬁcantly lower
delivery rates than those with negative ATA (ﬁxed-effects
RR ¼ 0.856; 95% CI, 0.759e0.965; p ¼ 0.011; Figure S3). The het-
erogeneity test found low heterogeneity (I2 ¼ 28.3%) and Egger's
test found no sign of publication bias (p ¼ 0.614).
However, in subfertile euthyroid women without SCH under-
going ART, womenwith positive ATA showed a similar delivery rate
to those with negative ATA (ﬁxed-effects RR ¼ 0.935; 95% CI,
0.785e1.112; p ¼ 0.446; Figure 4). No sign of heterogeneity was
detected (I2 ¼ 0%) and Egger's test found no sign of publication bias
(p ¼ 0.955).
Discussion
The present meta-analysis sought to estimate the effect of ATA
status alone on pregnancy outcomes in euthyroid women under-
going ART. It was found that in subfertile euthyroid women whose
SCH status is unknown, ATA was associated with increased
miscarriage rate and decreased delivery rate, but was not related to
pregnancy rate. In subfertile euthyroid women without SCH, the
present study did not detect a signiﬁcant effect of ATA status on
pregnancy rate, miscarriage rate, and delivery rate.An unexpected result was that the pooled miscarriage and de-
livery rate in subfertile euthyroid women whose SCH status is un-
known were contrary to those in subfertile euthyroid women
without SCH. We propose three reasons for this: (1) that the
number of studies on women without SCH may have been insuf-
ﬁcient to detect a difference; (2) that TA per se may not affect
miscarriage and delivery rates; or (3) it may only occur in women
with high concentrations of TSH.
Our ﬁndings could provide useful inferences on the importance
of TA on miscarriage, although its direct inﬂuence on miscarriage is
still unclear. The most popular hypothesis is that TA exerts its effect
in both a TSH-independent and TSH-dependent manner [33]. The
former implies that ATA level may be an indication of autoimmune
dysfunction such as increased endometrial T cell population, hy-
peractivity, and elevated mass of natural killer cells and activated
polyclonal B cells. In ATA-positive women, these immunological
factors were activated, and attacked trophoblast-placental tissue,
leading to miscarriage and fetal wastage. One study [18] concluded
that ATA per se may play a role, because it interferes with fertil-
ization and subsequent embryo development or implantation by
binding to the surface of the egg and/or embryo or attacking the
endometrium. However, evidence of a TSH-independent mecha-
nism was limited. First, there was no dose-dependent effect be-
tween the titer of ATA and miscarriage [1]. In addition, the effect of
immunological therapy is still in doubt. Only one study [34]
compared the effect of heparin/aspirin therapy alone versus hep-
arin/aspirin in combination with intravenous immunoglobulin
(IVIg) immunotherapy on IVF outcomes of patients with positive
ATA. The study found that IVIg was linked to increased live birth
rate, but had no effect on miscarriage rate. Finally, there was no
direct evidence to prove any of the above proposed mechanisms.
Owing to the association between TSH levels and TA, a TSH-
dependent mechanism was also proposed. Our study may provide
evidence for the existence of a TSH-dependent mechanism, but the
pathogenesis is still unclear. It has been found that TSH could
stimulate the immune system by increasing the proliferative ca-
pacity and activity of natural killer cells, which might be respon-
sible for miscarriage [35]. Another hypothesis was that it was high-
Table 1
Characteristics of the included studies.
Source Inclusion criteria, patient characteristics Study groups Outcome measures ATA type, threshold
Karacan et al [28],
Turkey, 253 women,
prospective, ICSI
Women <42 y, with normal TSH and fT4,
ACA() and LAC(), normal uterine cavity,
no adjuvant treatment (thyroid hormones
and glucocorticoids) during study,
produced at least three oocytes in response
to ovarian stimulation, ﬁrst ART procedure,
men with morphologically normal
spermatozoa
n ¼ 34 ATA(þ)
n ¼ 219 ATA()
Implantation rate, positive
pregnancy test rate,
biochemical pregnancy rate,
clinical pregnancy rate,
miscarriage rate, ongoing
pregnancy rate
TPO-Ab and Tg-Ab, threshold
<35 IU/ml (TPO-Ab), <115 IU/
ml (Tg-Ab)
Chai et al [8], Hong
Kong, 627 women,
prospective, IVF/ICSI
First IVF/ICSI cycles, serum samples were
taken 6 mo prior to ovarian stimulation,
women with history of thyroid disease,
cycles for PGD and using donor oocytes
were excluded
n ¼ 89 ATA(þ) and
euthyroid
n ¼ 33 ATA(þ) and
subclinical
n ¼ 419 ATA() and
euthyroid
n ¼ 86 ATA() and
subclinical
Clinical pregnancy rate,
miscarriage rate, live birth rate
TPO-Ab and Tg-Ab, threshold
<9 IU/ml (TPO-Ab), <4 IU/ml
(Tg-Ab)
Kilic et al [30], Turkey,
79 women,
prospective, ICSI
First ART procedure, women with thyroid
pathologies, endocrine or systemic diseases,
history of miscarriage were excluded
n ¼ 31 ATA()
n ¼ 23 ATA(þ) without
treatment
n ¼ 23 ATA(þ) with
treatment
Biochemical pregnancy rate,
clinical pregnancy rate
TPO-Ab and Tg-Ab,threshold
<34 IU/ml (TPO-Ab), <115 IU/
ml (Tg-Ab)
Poppe et al [32],
Belgium, 234
women, prospective,
IVF/ICSI
First ART procedure, women with overt
thyroid dysfunction were excluded
n ¼ 32 ATA(þ)
n ¼ 202 ATA()
Pregnancy rate, miscarriage
rate, delivery rate
Only TPO-Ab, threshold <100
kU/L
Negro et al [11], Italy,
416 women,
retrospective, IVF/
ICSI
First ART procedure, women with overt
thyroid dysfunction or age >35 y were
excluded
n ¼ 42 ATA(þ)
n ¼ 374 ATA()
Pregnancy rate, miscarriage
rate, delivery rate
Only TPO-Ab, threshold <100
kU/L
Chi et al [29], China,
2419 women,
retrospective, IVF
First IVF procedure, euthyroid infertile
women
n ¼ 276 ATA(þ)
n ¼ 2143 ATA()
Clinical pregnancy rate,
miscarriage rate, live birth rate
TPO-Ab and Tg-Ab, threshold
was not clearly stated
Tan et al [27], Greece,
retrospective, 835
women, ICSI
First ICSI procedure, euthyroid healthy
women receiving ART exclusively for male
infertility reasons, women with reported
thyroid disease, intake of thyroid
medication and incomplete questionnaire
data were excluded
n ¼ 110 ATA(þ)
n ¼ 725 ATA()
Clinical pregnancy rate,
miscarriage rate, birth rate,
gestational age, preterm rate,
very preterm rate
TPO-Ab and Tg-Ab, threshold
<100 U/L (TPO-Ab), <100 U/L
(Tg-Ab)
Negro et al [31], Italy,
prospective, 484
women, IVF/ICSI
First ART procedure, women with overt
thyroid dysfunction were excluded
n ¼ 36 ATA(þ) with
treatment
n ¼ 36 ATA(þ) without
treatment
n ¼ 412 ATA()
Pregnancy rate, miscarriage
rate, delivery rate
Only TPO-Ab, threshold <100
kU/L
ART ¼ assisted reproductive technologies; ATA ¼ positive antithyroid antibodies; ICSI ¼ intracytoplasmic sperm injection; IVF ¼ in vitro fertilization; LAC ¼ lupus antico-
agulant; SCH ¼ subclinical hypothyroidism; Tg-Ab ¼ antibodies against thyroglobulin; TPO-Ab ¼ antibodies against thyroid peroxidase; TSH ¼ thyroid stimulating hormone.
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[11]. This could account for the difference in the effect of ATA be-
tween subfertile euthyroid women whose SCH status is unknown
and subfertile euthyroid womenwithout SCH in our meta-analysis.
The evidence for the effect of SCH on miscarriage is more
compelling than that for TA. First, in a recent meta-analysis [3], itTable 2
Quality assessment of included studies.
Source Selection
Representativeness of
the exposed cohort
Selection of the
nonexposed cohort
Ascertainment
of exposure
In
di
Karacan et al [28] ✰ ✰ ✰ ✰
Chai et al [8] ✰ ✰ ✰ ✰
Kilic et al [30] ✰ ✰ ✰ ✰
Poppe et al [32] ✰ ✰ ✰ ✰
Negro et al [11] ✰ ✰ ✰ ✰
Chi et al [29] ✰ ✰ ✰ ✰
Tan et al [27] ✰ ✰ ✰ ✰
Negro et al [31] ✰ ✰ ✰ ✰
A study can be awarded a maximum of one star for each numbered item within the s
comparability.was found that SCH was associated with a signiﬁcantly increased
risk of pregnancy loss, including miscarriages, stillbirths, and
perinatal deaths. Second, the correlation between SCH and
miscarriage was more robust. It was proposed that mothers' de-
mand for thyroid hormone increased during gestation, resulting in
a more severe degree of SCH and a decrease in serumComparability Outcome Total score
cident
sease
Assessment of
outcome
Length of
follow up
Adequacy of
follow up
✰✰ d ✰ ✰ 8
✰✰ d ✰ ✰ 8
✰✰ d ✰ ✰ 8
d d ✰ ✰ 6
✰✰ d ✰ ✰ 8
d d ✰ d 5
✰✰ d ✰ ✰ 8
✰✰ d ✰ ✰ 8
election and outcome categories. A maximum of two stars (✰✰) can be given for
Figure 2. Forest plot of risk ratios (RR) and 95% conﬁdence interval (CI) of pooled studies comparing ATA-positive patients with ATA-negative controls in subfertile euthyroid
women without SCH undergoing ART according to clinical pregnancy rate. ART ¼ assisted reproductive technologies; ATA ¼ positive antithyroid antibodies; SCH ¼ subclinical
hypothyroidism.
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changes in T3 and T4 serum concentrations in mothers. One study
reported that fetal concentrations of T3 and T4 were 100 times
lower than those in maternal serum, and serum FT4 concentrations
were about one-third in their euthyroid mothers [36]. As a result,
even a slight reduction in maternal serum FT4 concentrations may
result in a signiﬁcant decrease in fetal concentration, which may
lead to the loss of pregnancy. Finally, a meta-analysis of three
randomized controlled trial with data on 220 patients found that
levothyroxine supplementation resulted in a signiﬁcantly higherFigure 3. Forest plot of risk ratios and 95% conﬁdence interval of pooled studies compar
without SCH undergoing ART according to miscarriage rate. ART ¼ assisted reproductive tedelivery rate and lower miscarriage rate in women with SCH un-
dergoing ART [3].
Two meta-analyses on the effect of TA on women undergoing
ART have been reported previously, but the results were conﬂicting.
Although one study [5] found no association between TA and
miscarriage in women undergoing IVF, another [12] reported that
TA was associated with a higher risk of miscarriage in euthyroid,
subfertile women undergoing IVF. The contrasting results may be
attributable to different study populations and design: whereas the
meta-analysis by Toulis et al [12] included only prospective studiesing ATA-positive patients with ATA-negative controls in subfertile euthyroid women
chnologies; ATA ¼ positive antithyroid antibodies; SCH ¼ subclinical hypothyroidism.
Figure 4. Forest plot of risk ratios and 95% conﬁdence interval of pooled studies comparing ATA-positive patients with ATA-negative controls in subfertile euthyroid women
without SCH undergoing ART according to delivery rate. ART ¼ assisted reproductive technologies; ATA ¼ positive antithyroid antibodies; SCH ¼ subclinical hypothyroidism.
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the study by van den Boogaard [5] had no rigorous inclusion criteria
on either patients or design. With a similar study population to the
study by Toulis et al [12], our results in euthyroid women with/
without SCH were consistent with their data on miscarriage, but
our study also detected a signiﬁcant difference in delivery rates
between ATA-positive and ATA-negative patients.
However, several limitations of the present study should be
considered. As mentioned above, the included studies used
different cutoff levels and different laboratory methods to measure
TSH concentration, therefore, the effects of SCH could not be totally
eliminated. In addition, although patients with SCH were excluded
as far as possible, TSH levels may not be equal between positive-
ATA and negative-ATA patients. Unfortunately, the pooled differ-
ence of TSH levels between groups could not be calculated because
of the lack of relative data in some articles, so the effect of normal-
range TSH in patients without SCH could not be determined.
Another limitation of our study is the small sample size, especially
the number of patients without SCH. Only four articles, including
1855 patients, met our inclusion criteria when we limited the TSH
concentration to within 5 mIU/mL, so the results should be regar-
ded with caution.
In conclusion, TA per se does not impair assisted reproductive
treatment outcomes in women without SCH, and the apparent
association between TA and miscarriage in women whose SCH
status is unknown may be related to underlying SCH or TSH-
dependent mechanisms. Our study has potentially provided use-
ful data on the association between TA andmiscarriage. However, it
is recommended that women with TA undergoing ART, especially
combined with SCH, be carefully monitored in case of miscarriage.
Finally, more randomized controlled trials should be conducted to
determine whether supplemental levothyroxine is needed for pa-
tients with TA.Conﬂicts of interest
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